Natco Pharma launches fixed dose combination of Sofosbuvir, Daclatasvir

02 Jul 2018 Evaluate

Natco Pharma under its brand Hepcinat Plus has launched the generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg Tablet, for the treatment of patients with chronic hepatitis C virus (HCV) infection. The company has launched Hepcinat Plus at Rs 17,500, for a bottle of 28 tablets.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

999.35 4.25 (0.43%)
18-May-2024 12:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.85
Dr. Reddys Lab 5812.50
Cipla 1403.90
Zydus Lifesciences 1104.45
Lupin 1661.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.